Lindsay T Fourman, M.D.

Dr. Fourman is an Assistant Professor of Medicine and board-certified endocrinologist in the Metabolism Unit at Massachusetts General Hospital (MGH). She leads a clinical research program geared toward elucidating mechanisms and treatment strategies for cardiometabolic disease. Specifically, she serves as Principal Investigator (PI) of an R01-funded clinical trial to evaluate tesamorelin as a strategy to improve physical function, muscle mass, and muscle quality among individuals predisposed to impaired physical function. Additionally, she is PI of an NIH K23-funded study to delineate cardiometabolic sequelae of in utero exposure to maternal infection. In her role as Associate Director of the MGH Lipid and Metabolism Associates Clinic, she has cultivated a clinical and research focus on genetic and acquired forms of lipodystrophy. She serves as site PI of a clinical trial to assess the efficacy and safety of metreleptin in patients with familial partial lipodystrophy. Moreover, she has established and leads the MGH Lipodystrophy Biorepository (ODYSSEY), which collects data and biospecimens from patients with lipodystrophy to understand mechanisms and treatment strategies of disease. Dr. Fourman directs the MGH Metabolic Disorders Conference, which seeks to meld clinical experience with scientific literature to develop best practices for various lipid and metabolic disorders.